Global Critical Limb Ischemia Treatment Market - Snapshot
The global critical limb ischemia treatment market is driven by rise in prevalence of critical limb ischemia. Growth of the market is also attributed to increase in awareness about critical limb ischemia and rich product pipeline.
Critical limb ischemia (CLI) is a severe peripheral arterial disease (PAD), wherein chronic inflammation associated with atherosclerosis (progressive thickening of arteries lining) causes reduced blood flow to the extremities (legs, feet, and hands), leading to severe pain and ulcers or sore. Major risk factors for critical limb ischemia comprise aging (people aged 60 or over are at high risk of developing this diseased condition), obesity, diabetes, high cholesterol level, smoking, sedentary lifestyle, and high blood pressure. Critical limb ischemia is associated with symptoms such as ischemic rest pain, gangrene, or tissue loss. Rise in prevalence of critical limb ischemia is anticipated to increase demand for therapeutics, which in turn is expected to drive the global critical limb ischemia treatment market. According to recent study, around 2 million to 3 million people suffer from critical limb ischemia in the U.S. Moreover, increase in health care expenditure and rise in the number of clinical trials are likely to propel the global critical limb ischemia treatment market.
Request Sample Of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2770
No comments:
Post a Comment